Europe Clinical Trials Market To Reach $41.76 Billion By 2033

October 2025 | Report Format: Electronic (PDF)

Europe Clinical Trials Market Growth & Trends

The Europe clinical trials market size is estimated to reach USD 41.76 billion by 2033, expanding at a CAGR of 7.6% from 2025 to 2033, according to a new report by Grand View Research, Inc. The rise in technological advancement for clinical trials is one of the key factors driving the market. The growing adoption of new technologies like artificial intelligence, big data analytics, blockchain, clinical trials payments, and patient engagement solutions among others have significantly contributed to the market growth. The COVID-19 pandemic had improved the adoption of virtual clinical trials in the region. Therefore, the growing adoption of new technologies is likely to promote the growth of the market.

The demand for personalized medicines has significantly improved in the region owing to significant research funding for personalized therapies by the European Commission. The aim of various countries in Europe is to collaborate research and health policy to accelerate the adoption of personalized medicine with the formation of the International Consortium for Personalized Medicine, which brings together health research funders and policymaking groups. Such activities are likely to promote market growth. The region suffers from growing disease variation and prevalence. A significant number of people in the region suffer from chronic and rare diseases.

For instance, the European Commission states that approximately 5,000-8,000 distinct rare diseases affect around 6-8% of the European population i.e., between 27 - 36 million. Thus, the high burden of rare diseases is likely to increase the demand for researchers to develop therapeutics for rare diseases. The rising cost associated with research studies has increased the demand for CROs in the region for conducting clinical trials. The partnership agreement between pharmaceutical companies and CROs is likely to promote market growth.

Europe was one the worst affected region by the COVID-19 pandemic, owing to which public organizations in the region made significant funding in research to boost the development of COVID-19 vaccines and diagnostics. For instance, in June 2020 the French president pledged to invest USD 679 million to support the development of COVID-19 vaccines. Owing to the pandemic several research centers were shut down due to the national lockdown implemented by the government authorities, owing to which several clinical trial organizations opted for in silico trials and virtual clinical trials to speed up the research process. Such actions had profited the growth of the market.

key Request a free sample copy or view report summary: Europe Clinical Trials Market Report

Europe Clinical Trials Market Report Highlights

Phase I trials segment is the fastest-growing segment in the market over the forecast period. This can be attributed to the significant R&D spending by public and private organizations to support new researches
The interventional trials studies segment dominated the market in 2024 owing to the greater accuracy offered by these studies, as compared to other clinical study designs
European countries such as Germany and the U.K. are spearheading the revenue share, as these have a large patient pool and the presence of advanced medical infrastructure

Europe Clinical Trials Market Segmentation

Grand View Research has segmented the Europe clinical trials market based on on phase, study design, indication, indication by study design, service, sponsor, and country:

Europe Clinical Trials Phase Outlook (Revenue, USD Million, 2021 - 2033)

Phase I
Phase II
Phase III
Phase IV

Europe Clinical Trials Study Design Outlook (Revenue, USD Million, 2021 - 2033)

Interventional Trials
Observational Trials
Expanded Access Trials

Europe Clinical Trials Indication Outlook (Revenue, USD Million, 2021 - 2033)

Autoimmune/Inflammation
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome (IBS)
- Others
Pain Management
- Chronic Pain
- Acute Pain
Oncology
- Blood Cancer
- Solid Tumors
- Others
CNS Conditions
- Epilepsy
- Parkinson's Disease (PD)
- Huntington's Disease
- Stroke
- Traumatic Brain Injury (TBI)
- Amyotrophic Lateral Sclerosis (ALS)
- Muscle Regeneration
- Others
Diabetes
Obesity
Cardiovascular Diseases
Others

Europe Clinical Trials Indication by Study Design Outlook (Revenue, USD Million, 2021 - 2033)

Autoimmune/Inflammation
- Interventional Trials
- Observational Trials
- Expanded Access Trials
Pain Management
- Interventional Trials
- Observational Trials
- Expanded Access Trials
Oncology
- Interventional Trials
- Observational Trials
- Expanded Access Trials
CNS Conditions
- Interventional Trials
- Observational Trials
- Expanded Access Trials
Diabetes
- Interventional Trials
- Observational Trials
- Expanded Access Trials
Obesity
- Interventional Trials
- Observational Trials
- Expanded Access Trials
Cardiovascular Diseases
- Interventional Trials
- Observational Trials
- Expanded Access Trials
Others
- Interventional Trials
- Observational Trials
- Expanded Access Trials